OFSA3.SA Ouro Fino Saúde Animal Participações S.A
- Market cap
- BRL 1.34B
- P/E
- 5.7x
- P/B
- 1.61x
- ROE
- 9.7%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OFSA3.SA undervalued?
Graham numberOFSA3.SA trades 36.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ouro Fino Saúde Animal Participações S.A fundamental analysis
No fundamental analysis for Ouro Fino Saúde Animal Participações S.A yet.
Ouro Fino Saúde Animal Participações S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ouro Fino Saúde Animal Participações S.A
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides…
Full company profileOuro Fino Saúde Animal Participações S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ouro Fino Saúde Animal Participações S.A annual financial statements (BRL; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 457M | 505M | 589M | 620M | 730M | 905M | 1.04B | 943M | 1.02B | 1.22B | 1.18B |
| Gross Profit | 230M | 268M | 324M | 308M | 374M | 447M | 528M | 433M | 518M | 633M | 605M |
| Operating Income | 8.85M | 66.4M | 98.0M | 71.8M | 102M | 141M | 177M | 81.0M | 867M | 236M | 181M |
| EBITDA | - | 88.8M | 125M | 95.7M | 134M | 173M | 217M | 128M | 246M | 291M | 203M |
| Net Income | -5.21M | 38.1M | 68.8M | 46.3M | 89.7M | 114M | 131M | -50.0M | 814M | 222M | 80.2M |
| EPS | -0.10 | 0.71 | 1.28 | 0.86 | 1.66 | 2.12 | 2.42 | -0.93 | 15 | 4.13 | 1.49 |
| Balance Sheet | |||||||||||
| Total Assets | 776M | 810M | 846M | 870M | 1.10B | 1.19B | 1.35B | 1.28B | 1.38B | 1.57B | 1.61B |
| Total Liabilities | 399M | 404M | 390M | 377M | 543M | 551M | 611M | 590M | 628M | 769M | 788M |
| Shareholders' Equity | 376M | 406M | 456M | 492M | 561M | 641M | 736M | 689M | 756M | 797M | 827M |
| Cash & Short-term Investments | 70.3M | 123M | 65.2M | 45.0M | 244M | 161M | 165M | 304M | 234M | 251M | 220M |
| Total Debt | 315M | 286M | 245M | 277M | 298M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 42.2M | 99.5M | 42.8M | 56.4M | 112M | 46.5M | 89.6M | 190M | 73.9M | 99.9M | 365M |
| Capital Expenditure | 85.3M | 31.8M | 48.3M | 52.1M | 24.5M | 55.9M | 52.0M | 47.7M | 44.7M | 47.3M | 17.6M |
| Free Cash Flow | - | 67.7M | -5.52M | 4.26M | 87.4M | -19.7M | 19.4M | 143M | 29.2M | 52.6M | 348M |
| Ratios | |||||||||||
| ROE | -1.4% | 9.4% | 15.1% | 9.4% | 16.0% | 17.8% | 17.8% | -7.2% | 107.7% | 27.9% | 9.7% |
| ROA | -0.7% | 4.7% | 8.1% | 5.3% | 8.1% | 9.6% | 9.7% | -3.9% | 58.8% | 14.2% | 5.0% |
| Net Profit Margin | -1.1% | 7.5% | 11.7% | 7.5% | 12.3% | 12.6% | 12.6% | -5.3% | 79.5% | 18.1% | 6.8% |
| Debt to Equity | 0.84x | 0.70x | 0.54x | 0.56x | 0.53x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ouro Fino Saúde Animal Participações S.A dividends
- Dividend yield
- 2.61%
- Forward dividend
- 1.29 BRL
- Payout ratio
- 15.7%
- Ex-dividend date
- Apr 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | BRL 35.0M | 0.65 | 15.7% |
| 2024 | BRL 18.2M | 0.34 | 2.2% |
| 2023 | BRL 23.4M | 0.44 | - |
| 2022 | BRL 33.2M | 0.62 | 25.4% |
| 2021 | BRL 35.6M | 0.66 | 31.2% |
| 2020 | BRL 11.0M | 0.20 | 12.3% |
| 2019 | BRL 16.4M | 0.30 | 35.3% |
| 2018 | BRL 10.8M | 0.20 | 15.8% |
| 2017 | BRL 10.8M | 0.20 | 28.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ouro Fino Saúde Animal Participações S.A
- Insiders 86.16%
- Institutions 8.24%
- Public & others 5.60%
- Shares outstanding 53.8M
- Free float 7.28M
Ouro Fino Saúde Animal Participações S.A company profile
- Company name
- Ouro Fino Saúde Animal Participações S.A
- Ticker
- OFSA3.SA
- ISIN
- BROFSAACNOR7
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,086
- Fiscal year end
- December
- Address
- Rodovia Anhanguera SP 330, Cravinhos, SP, Brazil, 14140-000
- Phone
- 55 16 3518 2025
- Website
- ourofinosaudeanimal.com
About Ouro Fino Saúde Animal Participações S.A
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, products for animal reproduction, and vaccines; and performance-enhancing additives, probiotics, and other veterinary products for cattle, swine, poultry, sheep, horses, and goats, as well as manufacturing services. The company also manufactures veterinary solutions for dogs and cats, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products. In addition, it offers vaccines and other veterinary products for production and companion animals. The company was formerly known as A.H.N.S.P.E. Empreendimentos e Participações S.A. Ouro Fino Saúde Animal Participações S.A. was incorporated in 1987 and is headquartered in Cravinhos, Brazil.
Ouro Fino Saúde Animal Participações S.A management
5- Mr. Kleber Cesar Silveira GomesCEO & Member of Executive Board · born 1975
- Mr. Marcelo Da SilvaCFO, Member of Executive Board & Chief Investor Relations Officer · born 1979
- Mr. Tetsuhiko HiramatsuMember of Executive Board · born 1973
- Angelo MeloDirector - Strategic Development & New Business
- Bruno MenegazzoSupervisor of the Investor Relations Area